Cargando…

A new lymph node ratio-based staging system for rectosigmoid cancer: a retrospective study with external validation

BACKGROUND: This study evaluated the clinical value of a new American Joint Committee on Cancer (AJCC) tumor node metastasis (TNM) staging prediction model based on lymph node ratio (LNR) in rectosigmoid cancer (RSC). METHODS: The analysis included 1444 patients with nonmetastatic RSC diagnosed path...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chao, Zhao, Shutao, Wang, Xudong, Wen, Dacheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583910/
https://www.ncbi.nlm.nih.gov/pubmed/37462992
http://dx.doi.org/10.1097/JS9.0000000000000546
_version_ 1785122646746202112
author Zhang, Chao
Zhao, Shutao
Wang, Xudong
Wen, Dacheng
author_facet Zhang, Chao
Zhao, Shutao
Wang, Xudong
Wen, Dacheng
author_sort Zhang, Chao
collection PubMed
description BACKGROUND: This study evaluated the clinical value of a new American Joint Committee on Cancer (AJCC) tumor node metastasis (TNM) staging prediction model based on lymph node ratio (LNR) in rectosigmoid cancer (RSC). METHODS: The analysis included 1444 patients with nonmetastatic RSC diagnosed pathologically between 2010 and 2016 who were collected from the National Cancer Institute Surveillance, Epidemiology, and Results database. The AJCC N-stage was redefined according to the LNR cutoff point, and the ability of the new staging system to predict prognosis was compared with that of the AJCC TNM staging system. Data from 739 patients from our hospital were used for external validation. RESULTS: According to the number of examined lymph nodes and LNR, the N stage was divided into five groups (LNR0–5). The 5-year OS of patients divided according to the new T lymph node ratio M (TLNRM) staging into stage I (T1LNR1, T1LNR2), IIA (T1LNR3, T2LNR1, T2LNR2, T2LNR3, T1LNR4, T3LNR1), IIB (T2LNR4), IIC (T3LNR2, T4a LNR1, T1LNR5), IIIA (T3LNR3, T2LNR5, T4b LNR1, T4a LNR2, T3LNR4), IIIB (T3LNR5, T4a LNR3, T4a LNR4, T4b LNR2), and IIIC (T4b LNR3, T4a LNR5, T4b LNR4, T4b LNR5) was significantly different (P<0.05). Decision curve analysis showed that the net income of the new TLNRM staging system for different decision thresholds was higher than the prediction line of the traditional eighth TNM staging system. The smaller Akaike information criterion and Bayesian information suggested that the new staging system had a higher sensitivity for predicting prognosis than the traditional staging system. TLNRM II and III patients benefited from adjuvant chemotherapy, while adjuvant chemotherapy did not improve the prognosis of TNM II patients. These findings were confirmed by the external validation data. CONCLUSION: The new TLNRM staging system was superior to the eighth edition AJCC staging system for staging and predicting the prognosis of patients with RSC and may become an effective tool in clinical practice.
format Online
Article
Text
id pubmed-10583910
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105839102023-10-19 A new lymph node ratio-based staging system for rectosigmoid cancer: a retrospective study with external validation Zhang, Chao Zhao, Shutao Wang, Xudong Wen, Dacheng Int J Surg Original Research BACKGROUND: This study evaluated the clinical value of a new American Joint Committee on Cancer (AJCC) tumor node metastasis (TNM) staging prediction model based on lymph node ratio (LNR) in rectosigmoid cancer (RSC). METHODS: The analysis included 1444 patients with nonmetastatic RSC diagnosed pathologically between 2010 and 2016 who were collected from the National Cancer Institute Surveillance, Epidemiology, and Results database. The AJCC N-stage was redefined according to the LNR cutoff point, and the ability of the new staging system to predict prognosis was compared with that of the AJCC TNM staging system. Data from 739 patients from our hospital were used for external validation. RESULTS: According to the number of examined lymph nodes and LNR, the N stage was divided into five groups (LNR0–5). The 5-year OS of patients divided according to the new T lymph node ratio M (TLNRM) staging into stage I (T1LNR1, T1LNR2), IIA (T1LNR3, T2LNR1, T2LNR2, T2LNR3, T1LNR4, T3LNR1), IIB (T2LNR4), IIC (T3LNR2, T4a LNR1, T1LNR5), IIIA (T3LNR3, T2LNR5, T4b LNR1, T4a LNR2, T3LNR4), IIIB (T3LNR5, T4a LNR3, T4a LNR4, T4b LNR2), and IIIC (T4b LNR3, T4a LNR5, T4b LNR4, T4b LNR5) was significantly different (P<0.05). Decision curve analysis showed that the net income of the new TLNRM staging system for different decision thresholds was higher than the prediction line of the traditional eighth TNM staging system. The smaller Akaike information criterion and Bayesian information suggested that the new staging system had a higher sensitivity for predicting prognosis than the traditional staging system. TLNRM II and III patients benefited from adjuvant chemotherapy, while adjuvant chemotherapy did not improve the prognosis of TNM II patients. These findings were confirmed by the external validation data. CONCLUSION: The new TLNRM staging system was superior to the eighth edition AJCC staging system for staging and predicting the prognosis of patients with RSC and may become an effective tool in clinical practice. Lippincott Williams & Wilkins 2023-07-19 /pmc/articles/PMC10583910/ /pubmed/37462992 http://dx.doi.org/10.1097/JS9.0000000000000546 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Original Research
Zhang, Chao
Zhao, Shutao
Wang, Xudong
Wen, Dacheng
A new lymph node ratio-based staging system for rectosigmoid cancer: a retrospective study with external validation
title A new lymph node ratio-based staging system for rectosigmoid cancer: a retrospective study with external validation
title_full A new lymph node ratio-based staging system for rectosigmoid cancer: a retrospective study with external validation
title_fullStr A new lymph node ratio-based staging system for rectosigmoid cancer: a retrospective study with external validation
title_full_unstemmed A new lymph node ratio-based staging system for rectosigmoid cancer: a retrospective study with external validation
title_short A new lymph node ratio-based staging system for rectosigmoid cancer: a retrospective study with external validation
title_sort new lymph node ratio-based staging system for rectosigmoid cancer: a retrospective study with external validation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583910/
https://www.ncbi.nlm.nih.gov/pubmed/37462992
http://dx.doi.org/10.1097/JS9.0000000000000546
work_keys_str_mv AT zhangchao anewlymphnoderatiobasedstagingsystemforrectosigmoidcanceraretrospectivestudywithexternalvalidation
AT zhaoshutao anewlymphnoderatiobasedstagingsystemforrectosigmoidcanceraretrospectivestudywithexternalvalidation
AT wangxudong anewlymphnoderatiobasedstagingsystemforrectosigmoidcanceraretrospectivestudywithexternalvalidation
AT wendacheng anewlymphnoderatiobasedstagingsystemforrectosigmoidcanceraretrospectivestudywithexternalvalidation
AT zhangchao newlymphnoderatiobasedstagingsystemforrectosigmoidcanceraretrospectivestudywithexternalvalidation
AT zhaoshutao newlymphnoderatiobasedstagingsystemforrectosigmoidcanceraretrospectivestudywithexternalvalidation
AT wangxudong newlymphnoderatiobasedstagingsystemforrectosigmoidcanceraretrospectivestudywithexternalvalidation
AT wendacheng newlymphnoderatiobasedstagingsystemforrectosigmoidcanceraretrospectivestudywithexternalvalidation